TTK Healthcare Share Price

 Overview 

TTK Healthcare Limited is an Indian company engaged in healthcare and consumer wellness products. Established in 1958, the company operates across six business verticals, including consumer products, animal welfare, medical devices, protective devices, foods, and publications. TTK Healthcare Limited is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), reflecting its presence in India’s equity markets. TTK Healthcare share price today represents how the market evaluates its diversified operations and brand-based business structure. 

The company employs over two thousand five hundred people who support manufacturing, sales, and distribution activities across India. TTK Healthcare Limited also has an export presence in regions such as the United Kingdom, the United States of America, Germany, and parts of Southeast Asia. TTK Healthcare share trend has generally followed broader consumer healthcare demand patterns in India, especially as awareness around wellness products has increased over time. 

TTK Healthcare share price 2025-2026 has shown periods of consolidation along with gradual changes in valuation. TTK Healthcare stock price live is often used by investors to track movements within the mid-cap healthcare segment. TTK Healthcare stock price reflects the company’s multi-segment revenue model, supported by established brands in wellness, food, and medical product categories. 

TTK Healthcare Limited Company Fundamentals

A. Company Background 

TTK Healthcare Limited is a public limited company incorporated on 21 May 1958 in Chennai, Tamil Nadu, India, with Corporate Identification Number (CIN) L24231TN1958PLC003647. The company was originally incorporated as Orient Pharma Limited and was later renamed TTK Pharma in November 1981 before adopting its current name. It is part of the TTK Group and operates as a diversified healthcare and consumer products company engaged in pharmaceuticals, consumer products, medical devices, protective devices, foods, animal welfare products, and publications. The registered office is located at No. 6, Cathedral Road, Chennai. The company has developed integrated capabilities across manufacturing and marketing in multiple healthcare-related segments.  

B. Company Product Lines 

• Consumer Products Division  

• Foods Division  

• Protective Devices Division  

• Animal Welfare Division  

• Medical Devices Division – Orthopedics  

• Medical Devices Division – Heart Valve  

• Publications Division  

• Pharmaceutical / Ethical Products Division  

C. Company Revenue Model 

• Branded Consumer Products Sales  

• Revenue from baby care, personal care, home care, and sexual wellness products  

• Medical Devices and Healthcare Products  

• Income from heart valves, orthopedic implants, and related medical devices  

• Animal Welfare Products  

• Revenue from veterinary and livestock healthcare products  

• Food Products  

• Income from ready-to-fry and snack food products  

• Protective Devices  

• Revenue from condoms and allied products  

• Publications  

• Income from maps, atlases, and educational publications  

• Distribution and Sales Network  

• Revenue supported by extensive domestic distribution and institutional channels  

D. Geographic Presence 

• Registered Office  

• Chennai, Tamil Nadu, India  

• Manufacturing Facilities (India)  

• Pallavaram, Chennai – pharmaceutical and animal welfare products  

• Trivandrum, Kerala – heart valve manufacturing  

• Ambattur and Chromepet, Chennai – orthopedic division  

• Hosakote, Karnataka and Jaipur, Rajasthan – foods division  

• Virudhunagar, Tamil Nadu and Puducherry – protective devices division  

• Distribution Network  

• Presence across India through depots, distributors, and retail network  

• International Presence  

• Export operations to multiple global markets  

E. Leadership 

Key leaders as of March 2026: 

• T. T. Raghunathan – Executive Chairman  

• V. Ranganathan – Executive Director, Managing Director & Chief Executive Officer  

• B. V. K. Durga Prasad – President (Finance) & Chief Financial Officer  

• S. Ranganath Rao – President (Food Division)  

• Brijj Balaji Singh – President (Protective Devices Division)  

• Yogesh Yadav – President (Consumer Products)  

• K. Sunil – President (Heart Valve)  

• P. A. Venkateswaran – Business Head (Orthopaedics)  

• Dr. V. Senthil Kumar – Senior Vice President (Sales & Marketing)  

• Vishal Vyas – Assistant Vice President (Marketing)  

• V. K. Srinivasan – Senior Vice President (Finance)  

• R. Srikanth – Senior Vice President (Systems)  

• Arjun Siva – Deputy General Manager (Marketing)  

• Baskar N – Assistant Vice President (Operations)  

• V. K. Murugesan – Assistant Vice President (Operations)  

• M. S. Sunil Kumar – Senior General Manager (Sales & Marketing)  

• Gowry A. Jaishankar – Company Secretary & Deputy General Manager (Legal)  

• K. Shankaran – Non-Executive & Non-Independent Director  

• R. K. Tulshan – Non-Executive & Non-Independent Director  

• Murali Neelakantan – Independent Director  

• T. T. Mukund – Non-Executive & Non-Independent Director  

• Hastha Shivaramkrishnan – Independent Director  

• Subashree Anantkrishnan – Independent Director  

• V. Sundaresan – Additional Independent Director  

• N. Ramesh Rajan – Independent Director 

F. Key Milestones 

• 1958: Incorporated as Orient Pharma Limited  

• 1959: Commenced production of Woodward’s Gripe Water in Chennai  

• 1976: Pharmaceutical division merged into TTK Healthcare structure  

• 1981: Renamed as TTK Pharma  

• 1990s: Introduction and commercialization of TTK Chitra Heart Valve  

• 2000s: Expansion into multiple divisions including foods, protective devices, and medical devices  

• 2022: Divestment of Human Pharma division  

• 2023–24: Expansion of protective devices manufacturing capacity (Virudhunagar) 

G. Industry Perspective 

India’s healthcare and consumer wellness industry has demonstrated structural expansion, driven by rising per-capita health expenditure and deepening health awareness across urban and semi-urban markets. The animal welfare sector has continued to grow, propelled by dairy productivity demands and the accelerating pet humanisation trend nationwide. India’s sexual wellness and male contraceptives market has recorded significant volume and value growth as of calendar year 2024, signalling accelerating consumer acceptance across demographics. The medical devices space has evolved under progressive regulatory formalisation, creating quality differentiation opportunities for domestic manufacturers. India’s consumer healthcare segment has remained resilient through macroeconomic cycles, underpinned by consistent domestic demand. TTK Healthcare has aligned its multi-segment portfolio strategy with these structural industry trends as of FY 2024-25. TTK Healthcare share price has demonstrated sensitivity to sectoral demand momentum. TTK Healthcare stock price has remained reflective of the company’s cross-industry sub-sector exposure. TTK Healthcare Limited Stock Market Presence – Listing And Index Representation 

TTK Healthcare Limited is listed on the Bombay Stock Exchange (BSE) under the code 507747 and on the National Stock Exchange (NSE) under the symbol TTKHLTCARE. The company’s International Securities Identification Number (ISIN) is INE910C01018. It has been publicly traded for several decades following its incorporation in May 1958, although the exact listing date is not specified in the FY 2024-25 Annual Report or on its official website. 

As of FY 2024-25, TTK Healthcare Limited has not been included in major stock market indices such as the BSE Sensex, NSE Nifty 50, Nifty Midcap 100, or Nifty Smallcap 250. Its trading activity reflects characteristics of a small-cap stock, including moderate liquidity and relatively lower daily trading volumes compared to larger companies. 

TTK Healthcare share price is followed by both retail and institutional investors, while TTK Healthcare stock price remains a reference point in daily market activity. TTK Healthcare earnings announcements play an important role in influencing market sentiment, particularly during quarterly financial disclosures. 

TTK Healthcare Limited Stock Performance And Share Price History 

TTK Healthcare share price has shown different phases of movement over the five-year period from FY 2020-21 to FY 2024-25. The five-year Compound Annual Growth Rate (CAGR) indicates a gradual accumulation pattern rather than sharp growth. During this period, TTK Healthcare stock price has experienced consolidation phases, especially during broader changes in the healthcare sector. 

Over the three-year period from FY 2022-23 to FY 2024-25, the three-year CAGR has remained moderate. This trend has been influenced by internal changes, including the divestment of the Human Pharma Division in FY 2021-22. TTK Healthcare share price history also shows a period of decline during parts of FY 2024-25 following earlier upward movement. 

TTK Healthcare investor sentiment has shown signs of stabilisation as the company continues to diversify its revenue streams. TTK Healthcare volatility has remained consistent with other small-cap healthcare stocks, with price changes often occurring around earnings announcements and corporate developments. 

TTK Healthcare Limited Investor Relevance And Role In Portfolio 

TTK Healthcare investment considerations are based on its diversified business structure, established brands, and debt-free balance sheet as of FY 2024-25. TTK Healthcare share price has reflected steady market interest linked to its consumer healthcare portfolio and operational consistency. 

TTK Healthcare fundamentals indicate stable cash flows and gradual improvement in profitability in recent years. TTK Healthcare P/E ratio (Price-to-Earnings ratio) has remained within ranges similar to other diversified healthcare companies. TTK Healthcare EPS (Earnings Per Share) has shown year-on-year growth, particularly after the company exited lower-margin pharmaceutical operations. 

TTK Healthcare live price is monitored by investors who are building medium-to-long-term positions in the consumer healthcare segment. TTK Healthcare performance is regularly evaluated by market participants as part of portfolio assessment during FY 2024-25. 

TTK Healthcare Limited Sectoral Relevance And Peer Positioning 

TTK Healthcare peer comparison places the company within the diversified healthcare and consumer products category. Companies mentioned in FY 2024-25 disclosures for comparison include 3M India Limited, DCM Shriram Limited, Balmer Lawrie and Company Limited, and Andrew Yule and Company Limited. These companies operate across multiple sectors, similar to TTK Healthcare Limited, but differ in their core focus areas. 

TTK Healthcare Limited has a more focused presence in domestic branded health categories such as infant care, sexual wellness, and veterinary nutrition. TTK Healthcare market cap places it in the small-cap segment, with moderate free-float availability. Retail investors form a significant portion of its shareholder base, while institutional participation remains limited. 

TTK Healthcare SWOT analysis highlights its long-standing brands, including Woodward’s and Skore, as key strengths. At the same time, its smaller scale compared to large-cap healthcare companies remains an important factor in competitive positioning. 

Summary 

TTK Healthcare Limited operates as a diversified healthcare and consumer wellness company with a long market presence. Its listing on both BSE and NSE provides accessibility to investors, while its small-cap classification reflects moderate liquidity and scale. TTK Healthcare share price movements have remained aligned with sector trends and internal business changes. The company’s financial performance, supported by stable cash flows and improving earnings, contributes to its relevance in investor portfolios. Its position within the healthcare and consumer products sector is shaped by brand presence, diversified operations, and consistent participation in India’s equity markets.